Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.34 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117019 | 0.94 | TSHR (0.36) | MLYCDTSHRSLC16A3SLC16A1GRIA2 | |
| SCHEMBL2005077 | 0.94 | TSHR (0.36) | MLYCDTSHRSLC16A3SLC16A1GRIA2 | |
| SCHEMBL20207409 | 0.90 | TSHR (0.36) | TSHRSLC16A3SLC16A1GRIA2USP2 | |
| SCHEMBL7602428 | 0.85 | TSHR (0.40) | TSHRUSP2HSD17B10CRHR1HTT | |
| SCHEMBL20207415 | 0.85 | TSHR (0.40) | TSHRUSP2HSD17B10CRHR1HTT | |
| SCHEMBL14947359 | 0.78 | CYP2C19 (0.40) | TSHRGRIA2HSD17B10ALDH1A1 | |
| SCHEMBL4447508 | 0.74 | EGFR (0.42) | TSHRALDH1A1CNR2 | |
| SCHEMBL4222294 | 0.74 | EGFR (0.42) | TSHRALDH1A1CNR2 | |
| SCHEMBL12237636 | 0.73 | TSHR (0.33) | TSHRUSP2HSD17B10CRHR1HTT | |
| SCHEMBL12304298 | 0.72 | CNR2 (0.44) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1683784-A1 | DIIMONIUM SALT COMPOUND AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050148786-A1 | Diimmonium compound and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148786-A1 | Diimmonium compound and use thereof | INO80, ARID2, TAS2R9 | MLYCD 3703/4885TSHR 584/4885SLC16A3 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.